Strategic Acquisition Ectosense's acquisition by ResMed in 2021 highlights its strategic importance within the sleep disorder diagnostics market, suggesting potential for collaboration or integration with ResMed's extensive healthcare solutions.
Innovative Technology The company's development of accessible, cloud-connected home sleep testing devices like NightOwl presents opportunities for partnerships centered on remote healthcare delivery and telemedicine platforms.
Market Niche Focusing on diagnostic sleep testing for the large global population suffering from sleep disorders, Ectosense offers a targeted solution that could benefit from expanded distribution channels or telehealth service integrations.
Funding and Growth Securement of seed funding and strategic partnerships positions Ectosense as a growth-stage company open to further investments or collaborations aimed at scaling its sleep diagnostics technology.
Industry Collaborations Partnerships like MedCall Advisors suggest opportunities to develop integrated sleep apnea screening solutions with healthcare providers, payers, or telehealth companies seeking remote diagnostic tools.
Ectosense uses 8 technology products and services including Varnish, Segment, Google Fonts API, and more. Explore Ectosense's tech stack below.
| Ectosense Email Formats | Percentage |
| First.Last@ectosense.com | 50% |
| First.Last@ectosense.com | 50% |
Hospitals and Health CareFlanders, Belgium0-1 Employees
Ectosense was acquired by ResMed (NYSE:RMD) in October 2021. It was a health-tech venture that developed accessible diagnostic sleep testing equipment to help restore the sleep of the one billion people that suffer from a sleep disorder.
Company Overview
Funding & FinancialsEctosense's revenue is estimated to be in the range of $1M
Funding & FinancialsEctosense's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com